Manufacturer of Controlled Substances; Notice of Registration; Nektar Therapeutics, 67677 [2012-27567]

Download as PDF Federal Register / Vol. 77, No. 219 / Tuesday, November 13, 2012 / Notices 67677 1301.33, the above named company is granted registration as a bulk manufacturer of the basic class of controlled substance listed. NATIONAL AERONAUTICS AND SPACE ADMINISTRATION prior to the meeting to Charlene Williams. [Notice 12–095] Dated: November 5, 2012. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. NASA Advisory Council; Audit, Finance and Analysis Committee; Meeting Patricia D. Rausch, Advisory Committee Management Officer, National Aeronautics and Space Administration. National Aeronautics and Space Administration. ACTION: Notice of Meeting. AGENCY: [FR Doc. 2012–27568 Filed 11–9–12; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration; Nektar Therapeutics srobinson on DSK4SPTVN1PROD with By Notice dated July 17, 2012, and published in the Federal Register on July 26, 2012, 77 FR 43862, Nektar Therapeutics, 1112 Church Street, Huntsville, Alabama 35801, made application by letter to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Fentanyl (9801), a basic class of controlled substance listed in schedule II. The company plans to manufacture the listed controlled substance in support of product development. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Nektar Therapeutics to manufacture the listed basic class of controlled substance is consistent with the public interest at this time. DEA has investigated Nektar Therapeutics to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems; verification of the company’s compliance with state and local laws; and review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic class of controlled substance listed. Dated: November 5, 2012. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2012–27567 Filed 11–9–12; 8:45 am] BILLING CODE 4410–09–P VerDate Mar<15>2010 17:08 Nov 09, 2012 In accordance with the Federal Advisory Committee Act, Public Law 92–463, as amended, the National Aeronautics and Space Administration announces a meeting of the Audit, Finance and Analysis Committee of the NASA Advisory Council. DATES: Monday, November 26, 2012, 9:00 a.m.–5:15 p.m., Local Time. ADDRESS: NASA Headquarters. 300 E Street SW., Conference Room 8E40, Washington DC 20546. FOR FURTHER INFORMATION CONTACT: Ms. Charlene Williams, Office of the Chief Financial Officer, National Aeronautics and Space Administration Headquarters, Washington, DC 20546. Phone: 202–358–2183. SUPPLEMENTARY INFORMATION: The agenda for the meeting includes briefings on the following topics: • FY 2012 Financial Statement Audit • FY 2013 Financial Management Initiatives • Administrative Savings • NASA Budget • Government Accounting Office High Risk List • Financial System Initiative It is imperative that the meeting be held on these dates to accommodate the scheduling priorities of the key participants. Attendees will be requested to sign a register and to comply with NASA security requirements, including the presentation of a valid picture ID to NASA Security before access to NASA Headquarters. Foreign Nationals attending this meeting will be required to provide a copy of their passport and visa in addition to providing the following information no later than November 21, 2012: full name; gender; date/place of birth; citizenship; visa information (number, type, expiration date); passport information (number, country, expiration date); employer/ affiliation information (name of institution, address, country, telephone); title/position of attendee; and home address to Charlene Williams at fax: (202) 358–4336. U.S. Citizens and Permanent Residents (green card holders) are requested to submit their name and affiliation 3 working days SUMMARY: Jkt 229001 PO 00000 Frm 00051 Fmt 4703 Sfmt 4703 [FR Doc. 2012–27487 Filed 11–9–12; 8:45 am] BILLING CODE P NATIONAL CREDIT UNION ADMINISTRATION Sunshine Act; Notice of Agency Meeting 10:00 a.m., Thursday, November 15, 2012. PLACE: Board Room, 7th Floor, Room 7047, 1775 Duke Street, Alexandria, VA 22314–3428. STATUS: Open. MATTERS TO BE CONSIDERED: 1. NCUA’s 2013 Operating Budget. 2. NCUA/NCUSIF Overhead Transfer Rate. 3. Federal Credit Unions’ Operating Fee Scale. 4. Board Briefing on the Estimated 2013 Premium Ranges for the NCUSIF and the Corporate Stabilization Fund. FOR FURTHER INFORMATION CONTACT: Mary Rupp, Secretary of the Board, Telephone: 703–518–6304. TIME AND DATE: Mary Rupp, Board Secretary. [FR Doc. 2012–27648 Filed 11–8–12; 4:15 pm] BILLING CODE 7535–01–P NATIONAL SCIENCE FOUNDATION Astronomy and Astrophysics Advisory Committee #13883; Notice of Meeting In accordance with the Federal Advisory Committee Act (Pub. L. 92– 463, as amended), the National Science Foundation announces the following Astronomy and Astrophysics Advisory Committee (#13883) meeting: Date and Time: November 30, 2012, 8:30 a.m.–5:00 p.m.; December 1, 2012, 8:30 a.m.– 1:00 p.m. Place: National Science Foundation, Room 1235, Stafford I Building, 4201 Wilson Blvd., Arlington, VA, 22230. Type of Meeting: Open. Contact Person: Dr. Jim Ulvestad, Division Director, Division of Astronomical Sciences, Suite 1045, National Science Foundation, 4201 Wilson Blvd., Arlington, VA 22230. Telephone: 703–292–7165. Purpose of Meeting: To provide advice and recommendations to the National Science Foundation (NSF), the National Aeronautics and Space Administration (NASA) and the U.S. Department of Energy (DOE) on issues E:\FR\FM\13NON1.SGM 13NON1

Agencies

[Federal Register Volume 77, Number 219 (Tuesday, November 13, 2012)]
[Notices]
[Page 67677]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-27567]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Registration; 
Nektar Therapeutics

    By Notice dated July 17, 2012, and published in the Federal 
Register on July 26, 2012, 77 FR 43862, Nektar Therapeutics, 1112 
Church Street, Huntsville, Alabama 35801, made application by letter to 
the Drug Enforcement Administration (DEA) to be registered as a bulk 
manufacturer of Fentanyl (9801), a basic class of controlled substance 
listed in schedule II.
    The company plans to manufacture the listed controlled substance in 
support of product development.
    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. 823(a) and determined that the registration of 
Nektar Therapeutics to manufacture the listed basic class of controlled 
substance is consistent with the public interest at this time. DEA has 
investigated Nektar Therapeutics to ensure that the company's 
registration is consistent with the public interest. The investigation 
has included inspection and testing of the company's physical security 
systems; verification of the company's compliance with state and local 
laws; and review of the company's background and history. Therefore, 
pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, 
the above named company is granted registration as a bulk manufacturer 
of the basic class of controlled substance listed.

    Dated: November 5, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2012-27567 Filed 11-9-12; 8:45 am]
BILLING CODE 4410-09-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.